Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
- PMID: 17513814
- DOI: 10.1200/JCO.2006.08.3998
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
Erratum in
- J Clin Oncol. 2007 Aug 1;25(22):3387.
Abstract
Purpose: Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung cancer (SCLC) after failure of first-line chemotherapy. This open-label, randomized, phase III study compared oral and IV topotecan in patients with SCLC sensitive to initial chemotherapy.
Patients and methods: Patients with limited- or extensive-disease SCLC, documented complete or partial response to first-line therapy, Eastern Cooperative Oncology Group performance status < or = 2, and measurable recurrent disease (WHO criteria) with a treatment-free interval of > or = 90 days were assigned to treatment with either oral topotecan 2.3 mg/m2/d on days 1 through 5 or IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days. Primary end point was response rate as confirmed by an external reviewer blinded to treatment.
Results: A total of 309 patients were randomly assigned. In intent-to-treat analysis, response rates were 18.3% with oral topotecan (n = 153) and 21.9% with IV topotecan (n = 151), with a difference (oral -IV) of -3.6% (95% CI, -12.6% to 5.5%). Median survival time was 33.0 weeks for oral and 35.0 weeks for IV topotecan; 1- and 2-year survival rates were 32.6% and 12.4% for oral topotecan, respectively, and 29.2% and 7.1% for IV topotecan, respectively. Third-line chemotherapy was similar for both groups (33% for oral; 35% for IV). Incidence of grade 4 toxicity in patients who received oral and IV topotecan was as follows: neutropenia in 47% and 64%, thrombocytopenia in 29% and 18%, grade 3 or 4 anemia in 23% and 31%, and sepsis in 3% and 3%, respectively. The most frequent nonhematologic adverse events (all grades) included nausea (43% oral; 42% IV), alopecia (26% oral; 30% IV), fatigue (31% oral; 36% IV), and diarrhea (36% oral; 20% IV).
Conclusion: Oral topotecan demonstrates activity and tolerability similar to IV topotecan in chemotherapy-sensitive SCLC patients and offers patients a convenient alternative to IV therapy.
Similar articles
-
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.J Clin Oncol. 2006 May 1;24(13):2044-51. doi: 10.1200/JCO.2005.03.3332. J Clin Oncol. 2006. PMID: 16648504 Clinical Trial.
-
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.J Clin Oncol. 2006 Dec 1;24(34):5441-7. doi: 10.1200/JCO.2006.06.5821. J Clin Oncol. 2006. PMID: 17135646 Clinical Trial.
-
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.Clin Cancer Res. 2003 Jan;9(1):143-50. Clin Cancer Res. 2003. PMID: 12538462 Clinical Trial.
-
Topotecan in the treatment of recurrent small cell lung cancer: an update.Oncologist. 2004;9 Suppl 6:4-13. doi: 10.1634/theoncologist.9-90006-4. Oncologist. 2004. PMID: 15616145 Review.
-
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.Oncologist. 2005 Oct;10(9):686-94. doi: 10.1634/theoncologist.10-9-686. Oncologist. 2005. PMID: 16249347 Review.
Cited by
-
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial.Cancer Pathog Ther. 2024 Feb 7;2(4):268-275. doi: 10.1016/j.cpt.2024.02.001. eCollection 2024 Oct. Cancer Pathog Ther. 2024. PMID: 39371104 Free PMC article.
-
Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.Ther Adv Med Oncol. 2024 Sep 19;16:17588359241272957. doi: 10.1177/17588359241272957. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39355343 Free PMC article.
-
Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.BMC Cancer. 2024 Oct 1;24(1):1218. doi: 10.1186/s12885-024-12935-x. BMC Cancer. 2024. PMID: 39354432 Free PMC article.
-
Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.BMC Cancer. 2024 Sep 27;24(1):1182. doi: 10.1186/s12885-024-12954-8. BMC Cancer. 2024. PMID: 39333988 Free PMC article. Clinical Trial.
-
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.EClinicalMedicine. 2024 Sep 3;75:102791. doi: 10.1016/j.eclinm.2024.102791. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39286636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical